Soleno Therapeutics Inc
SLNO
Company Profile
Business description
Soleno Therapeutics Inc is a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases. Its product candidate DCCR (Diazoxide Choline) Extended-Release tablets, is a proprietary extended-release formulation of a crystalline salt of diazoxide. DCCR has demonstrated the ability to activate the KATP channel in the brain, pancreas, and fat tissue.
Contact
100 Marine Parkway
Suite 400
Redwood CityCA94065
USAT: +1 650 213-8444
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
92
Stocks News & Analysis
stocks
Another incredible quarter from Microsoft
We were wrong when we thought last quarter would be hard to top.
stocks
10 best US dividend aristocrats to buy now—including a surprise outperformer
These undervalued stocks with wide and narrow moats have increased their dividends for 25 consecutive years or more.
stocks
Leading ASX players in this field look materially overvalued
We raise our Fair Value estimates but still think that current share prices rely on overly optimistic expectations.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,999.00 | 16.40 | -0.18% |
| CAC 40 | 7,771.97 | 89.99 | -1.14% |
| DAX 40 | 24,065.47 | 196.75 | -0.81% |
| Dow JONES (US) | 44,226.91 | 234.37 | -0.53% |
| FTSE 100 | 9,132.81 | 4.13 | -0.05% |
| HKSE | 24,773.33 | 403.60 | -1.60% |
| NASDAQ | 21,141.02 | 11.35 | 0.05% |
| Nikkei 225 | 41,069.82 | 415.12 | 1.02% |
| NZX 50 Index | 12,823.74 | 32.23 | -0.25% |
| S&P 500 | 6,348.75 | 14.15 | -0.22% |
| S&P/ASX 200 | 8,742.80 | 13.60 | -0.16% |
| SSE Composite Index | 3,573.21 | 42.51 | -1.18% |